(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Quince Therapeutics's earnings in 2025 is -$49,029,000.On average, 8 Wall Street analysts forecast QNCX's earnings for 2025 to be -$59,117,406, with the lowest QNCX earnings forecast at -$58,956,265, and the highest QNCX earnings forecast at -$57,527,478. On average, 8 Wall Street analysts forecast QNCX's earnings for 2026 to be -$39,162,730, with the lowest QNCX earnings forecast at -$66,535,282, and the highest QNCX earnings forecast at -$6,203,944.
In 2027, QNCX is forecast to generate -$35,477,964 in earnings, with the lowest earnings forecast at -$64,746,612 and the highest earnings forecast at -$1,691,985.